Review articlePublished 15 Jul 2016
Targeting angiogenesis in non-small-cell lung cancer: a focus on current approaches and future developments
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
We know how important antiangiogenesis therapy can be in cancer treatment. However, it took some time before the first compound became approved. Currently, several agents are approved and used against cancer. Moreover, the possible number of clinical indications and agents that are in development is extraordinary. A lot of questions regarding angiogenesis in cancer still remain unanswered. One of the major weaknesses is the fact that most of the approved agents do not have a predictive or prognostic biomarker that can be used to tailor these novel agents in terms of inducing the best possible antitumor effect. Many of these new targeted agents inhibit several tumorigenesis pathways, but most of the time only one of these pathways is the main driver for cancer proliferation. In this article, we present the most current clinical information available in antiangiogenic therapy and the potential development in non-small-cell lung cancer.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Practice
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Belisario A Arango”
- BylineArticles whose byline prints “Luis E Aguirre”
- BylineArticles whose byline prints “Cesar A Perez”
- BylineArticles whose byline prints “Michel Velez”
- BylineArticles whose byline prints “Edgardo S Santos”
- BylineArticles whose byline prints “Luis E Raez”